Angelica Tiotiu1, Nathalie Wirth1 and Yves Martinet1
of Pulmonology, CHRU,
In asthmatics patients,
is associated with accelerated decline in pulmonary function, poor
disease control and reduced responsiveness to corticosteroids.
Our objective was to compare
control efficiency in a population of asthmatic patients according to
We compared 3 equal groups of
asthmatics patients: group 1 never smokers, group 2 former smokers and
group 3 current smokers. We collected demographic, clinical data,
hospital anxiety/depression (HAD) score, functional respiratory data
and asthma control scores (ACQ6) for all patients.
The three groups were
identical in terms
of demographical data (mean age 42 vs 46 vs
44.5 years) and lung function: FEV1=80.6%, FVC=94.07%, FEV1/FVC=0.72 in
group 1, FEV1=80.9%, FVC=99.16%, FEV1/FVC=0.68 in group 2 and
FEV1=79.21%, FVC=96.04%, FEV1/FVC=0.69 in group 3 (p=0.457). Anxiety
defined by an HAD ≥8 was present in 46.67% patients in group 1,
53.33% in group 2 and 23.33% in group 3. Mean ACQ6 score was
significantly higher in group 3 vs group 2 (1.73 vs
1.23, p=0.003), and vs group 1 (1.17; p=0.003),
without significant difference between group 1 and 2 (p=0.416).
According to ACQ6, 9 patients in group 1 had an uncontrolled asthma, 11
in group 2 and 15 in group 3. Dyspnea sensation was significantly lower
in group 3 vs group 1 (p=0.047).
In conclusion, current
underestimated dyspnea, lower anxiety, and poorer asthma control than
nonsmokers or former smokers. These observations stress the importance
of smoking cessation to help achieve asthma control.